Vyndamax Shortage: What Providers and Prescribers Need to Know in 2026

As of 2026, Vyndamax (tafamidis 61 mg) is not listed on the FDA's Drug Shortage Database. Pfizer has maintained stable supply of the medication since its approval in May 2019. However, providers across cardiology and heart failure specialties routinely encounter patients who face significant delays in accessing Vyndamax — sometimes for weeks or months. This guide summarizes the current access landscape, the critical 2026 formulation change, the evolving ATTR-CM treatment market, and practical tools for ensuring patients remain on therapy.

No FDA Shortage, But Real Access Barriers

The access barriers providers observe are administrative and financial rather than supply-driven. The most common sources of patient access delay include:

• Specialty pharmacy onboarding: First-time prescriptions require benefits investigation, PA submission, and home delivery setup. This process alone can take 7–21 days at most specialty pharmacies.
• Prior authorization processing times: Most commercial plans and Medicare Part D plans require PA. Blue Cross Blue Shield, Aetna, and UnitedHealthcare all require PA for Vyndamax. Average commercial PA approval times range from 5–14 business days; denials requiring peer-to-peer review extend this by 1–2 weeks.
• Specialty tier placement: Nearly all commercial plans place Vyndamax on specialty tiers (Tier 4–6), with coinsurance ranging from 20–50% before copay assistance. This creates barriers for patients not yet enrolled in Pfizer's VyndaLink program.
• PA renewal failures: Annual PA renewals are required by most plans. Gaps in coverage due to missed renewal windows are a frequent cause of treatment interruption in established patients.

Critical 2026 Change: Vyndaqel Discontinuation

Pfizer has confirmed that Vyndaqel (tafamidis meglumine) — the 4-capsule, 80-mg formulation — will be discontinued after 2025. Going forward, Vyndamax (tafamidis 61 mg, one capsule daily) will be the sole tafamidis product available in the US.

Clinical and prescribing implications for providers:

• All existing Vyndaqel 80 mg prescriptions should be updated to Vyndamax 61 mg
• Vyndamax 61 mg and Vyndaqel 80 mg are bioequivalent in terms of systemic tafamidis exposure
• Vyndamax and Vyndaqel are NOT substitutable on a per-milligram basis — prescriptions must specify Vyndamax, not tafamidis meglumine at 61 mg
• Patients transitioned from Vyndaqel 20 mg (off-label or trial dose) should receive guidance — this is not equivalent to Vyndamax 61 mg and requires a new prescription

The Evolving ATTR-CM Treatment Landscape in 2026

Providers now have three FDA-approved disease-modifying therapies for ATTR-CM, representing a significant expansion from the single approved option available just two years ago:

• Vyndamax (tafamidis, Pfizer): TTR stabilizer; 61 mg once daily; gold standard since 2019; list price ~$268,000/year; patent extends to 2031
• Attruby (acoramidis, BridgeBio): TTR stabilizer; 712 mg (2 tablets) twice daily; FDA-approved November 2024; list price ~$245,000/year; growing market share with strong first-line usage as of Q1 2026
• Amvuttra (vutrisiran, Alnylam): TTR silencer (RNAi); 25 mg subcutaneous injection every 3 months; FDA-approved for ATTR-CM March 2025; list price ~$477,000/year; quarterly dosing may improve adherence for appropriate patients

A 2024 independent ICER analysis found current evidence insufficient to distinguish net health benefit between these agents as monotherapy in head-to-head comparisons. Treatment selection should be guided by patient-specific factors including NYHA class, adherence capacity, insurance formulary, and patient preference.

PA Documentation: What Payers Commonly Require

When submitting a prior authorization for Vyndamax, include:

• Confirmed ATTR-CM diagnosis (PYP scan results, cardiac MRI, or cardiac biopsy)
• NYHA classification (Class I–III typically required; Class IV may be denied)
• Echocardiographic data (wall thickness >12 mm is commonly cited by payers)
• Documentation that wild-type or hereditary ATTR-CM is the primary diagnosis
• Evidence of recent heart failure hospitalization or documented HF management

Pfizer's VynAssist Program for Providers

Pfizer's VynAssist program provides dedicated Field Access Specialists (FAS) who can support your practice with:

• Electronic PA submissions through CoverMyMeds (at no cost to your practice)
• Benefits verification and specialty pharmacy routing
• Enrollment of eligible patients in copay assistance (VyndaLink)
• Patient bridge supply coordination for new prescriptions while PA is processing

Contact Pfizer's Medical Affairs team at 1-888-863-1177, Monday–Friday, 9AM–6PM ET.

medfinder for Providers

medfinder for providers helps patients in your practice locate pharmacies that can fill their Vyndamax prescriptions. When specialty pharmacy routing is delayed or uncertain, medfinder identifies availability so patients don't interrupt therapy. See our dedicated guide on how to help your patients find Vyndamax in stock for practical steps.